Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.
Separately, JPMorgan Chase & Co. initiated coverage on Zealand Pharma A/S in a research note on Friday, November 8th. They set an "overweight" rating for the company.
Check Out Our Latest Research Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Performance
OTCMKTS:ZLDPF traded up $6.12 during midday trading on Tuesday, reaching $109.10. 698 shares of the company traded hands, compared to its average volume of 1,038. The company has a fifty day moving average price of $102.02 and a 200 day moving average price of $117.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The firm has a market capitalization of $7.75 billion, a price-to-earnings ratio of -44.90 and a beta of 0.89. Zealand Pharma A/S has a twelve month low of $65.26 and a twelve month high of $141.74.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Stories
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
